134 related articles for article (PubMed ID: 23495895)
21. JunB gene expression is inactivated by methylation in chronic myeloid leukemia.
Yang MY; Liu TC; Chang JG; Lin PM; Lin SF
Blood; 2003 Apr; 101(8):3205-11. PubMed ID: 12506033
[TBL] [Abstract][Full Text] [Related]
22. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Zion M; Ben-Yehuda D; Avraham A; Cohen O; Wetzler M; Melloul D; Ben-Neriah Y
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10722-6. PubMed ID: 7938018
[TBL] [Abstract][Full Text] [Related]
23. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
Li Z; Luo J
Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
[TBL] [Abstract][Full Text] [Related]
24. Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia.
Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; San Jose-Eneriz E; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
Leuk Res; 2008 Mar; 32(3):487-90. PubMed ID: 17765966
[TBL] [Abstract][Full Text] [Related]
25. SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia.
Wu DL; Wang Y; Zhang TJ; Chu MQ; Xu ZJ; Yuan Q; Ma JC; Lin J; Qian J; Zhou JD
Eur J Med Res; 2022 Nov; 27(1):259. PubMed ID: 36411451
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34
Maupetit-Mehouas S; Court F; Bourgne C; Guerci-Bresler A; Cony-Makhoul P; Johnson H; Etienne G; Rousselot P; Guyotat D; Janel A; Hermet E; Saugues S; Berger J; Arnaud P; Berger MG
Mol Oncol; 2018 Jun; 12(6):814-829. PubMed ID: 29575763
[TBL] [Abstract][Full Text] [Related]
27. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients.
Hernández-Boluda JC; Cervantes F; Colomer D; Vela MC; Costa D; Paz MF; Esteller M; Montserrat E
Exp Hematol; 2003 Mar; 31(3):204-10. PubMed ID: 12644017
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia.
Samaiya M; Bakhshi S; Shukla AA; Kumar L; Chauhan SS
J Cell Mol Med; 2011 Oct; 15(10):2189-99. PubMed ID: 21496199
[TBL] [Abstract][Full Text] [Related]
29. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
30. Expression and significance of DDX43 in lung adenocarcinoma.
Ma N; Xu HE; Luo Z; Zhou J; Zhou Y; Liu M
Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1491-1496. PubMed ID: 29044003
[TBL] [Abstract][Full Text] [Related]
31. Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
Zhang X; Yang L; Liu X; Nie Z; Wang X; Pan Y; Luo J
Br J Haematol; 2017 Sep; 178(5):728-738. PubMed ID: 28480959
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia.
Yang H; Liang H; Yan JS; Tao R; Hao SG; Ma LY
Int J Hematol; 2012 Jul; 96(1):65-73. PubMed ID: 22674382
[TBL] [Abstract][Full Text] [Related]
33. DDX43 mRNA expression and protein levels in relation to clinicopathological profile of breast cancer.
Amer NN; Khairat R; Hammad AM; Kamel MM
PLoS One; 2023; 18(5):e0284455. PubMed ID: 37200388
[TBL] [Abstract][Full Text] [Related]
34. [Methylation status of JunB and CDH13 gene promoter in CD34(+)CD38(-) chronic myelogenous leukemia cells].
Wang XJ; Li J; Fu BJ; Guo LL; Zhang JH; Huang SA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1405-8. PubMed ID: 20030915
[TBL] [Abstract][Full Text] [Related]
35. The DEAD-box protein DDX43 (HAGE) is a dual RNA-DNA helicase and has a K-homology domain required for full nucleic acid unwinding activity.
Talwar T; Vidhyasagar V; Qing J; Guo M; Kariem A; Lu Y; Singh RS; Lukong KE; Wu Y
J Biol Chem; 2017 Jun; 292(25):10429-10443. PubMed ID: 28468824
[TBL] [Abstract][Full Text] [Related]
36. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Jelinek J; Gharibyan V; Estecio MR; Kondo K; He R; Chung W; Lu Y; Zhang N; Liang S; Kantarjian HM; Cortes JE; Issa JP
PLoS One; 2011; 6(7):e22110. PubMed ID: 21760961
[TBL] [Abstract][Full Text] [Related]
37. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
[TBL] [Abstract][Full Text] [Related]
38. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
39. Tumor suppressor gene methylation on the short arm of chromosome 1 in chronic myelogenous leukemia.
Mori N; Ohwashi-Miyazaki M; Yoshinaga K; Okada M; Shiseki M; Motoji T; Tanaka J
Eur J Haematol; 2017 May; 98(5):467-477. PubMed ID: 28129457
[TBL] [Abstract][Full Text] [Related]
40. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
Amin HM; Hoshino K; Yang H; Lin Q; Lai R; Garcia-Manero G
J Pathol; 2007 Aug; 212(4):402-10. PubMed ID: 17503411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
